RxDoctor Payments Data

Lakshmidevi Putta, MD

Family Medicine · Burbank, CANPI 1962435628

Payments from drug & device makers

$2,587in general payments, 2019–2025

Across 120 payments — averaging $21.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$456
  • AbbVie$346
  • Shield Therapeutics Inc$285
  • Lilly USA, LLC$235
  • Hologic Sales And Service, LLC$166
  • AstraZeneca$165
  • plus $934 from 18 others

What the payments were for

  • Food & beverage$2,587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,587 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$115,452
Medicare patients
172
Services billed
1,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$27,465
MounjaroTirzepatide19$21,993
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,097
OzempicSemaglutide15$14,267
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$6,040
Breo ElliptaFluticasone/Vilanterol13$5,194
VascepaIcosapent Ethyl17$3,599
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,133
YuvafemEstradiol29$3,093
Candesartan Cilexetil39$2,833
SynthroidLevothyroxine Sodium35$2,110
Valsartan99$1,941
Raloxifene Hcl28$1,892
Nebivolol Hcl29$1,815
Atorvastatin Calcium189$1,657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$159$27,46524 claims
Lilly USA, LLCMounjaro$235$21,99319 claims
GSKTrelegy Ellipta, Breo Ellipta$456$20,29035 claims
Novo NordiskOzempic$45$14,26715 claims
AbbVieSynthroid$346$2,11035 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$104$1,546122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →